Возможные варианты применения препарата ламотриджин для эффективного лечения эпилепсии детей и подростков
Возможные варианты применения препарата ламотриджин для эффективного лечения эпилепсии детей и подростков
Бадалян О.Л., Савенков А.А. Возможные варианты применения препарата ламотриджин для эффективного лечения эпилепсии детей и подростков. Неврология и Ревматология (Прил. к журн. Consilium Medicum). 2018; 1: 10–15. DOI: 10.26442/2414-357X_2018.1.10-15
________________________________________________
Badalyan O.L., Savenkov A.A. Possible variants of lamotrigine for the effective treatment of epilepsy children and adolescents. Neurology and Rheumatology (Suppl. Consilium Medicum). 2018; 1: 10–15. DOI: 10.26442/2414-357X_2018.1.10-15
Возможные варианты применения препарата ламотриджин для эффективного лечения эпилепсии детей и подростков
Бадалян О.Л., Савенков А.А. Возможные варианты применения препарата ламотриджин для эффективного лечения эпилепсии детей и подростков. Неврология и Ревматология (Прил. к журн. Consilium Medicum). 2018; 1: 10–15. DOI: 10.26442/2414-357X_2018.1.10-15
________________________________________________
Badalyan O.L., Savenkov A.A. Possible variants of lamotrigine for the effective treatment of epilepsy children and adolescents. Neurology and Rheumatology (Suppl. Consilium Medicum). 2018; 1: 10–15. DOI: 10.26442/2414-357X_2018.1.10-15
Ламотриджин (Сейзар) – противоэпилептический препарат широкого спектра действия – более четверти века с успехом применяется в педиатрической эпилептологии. В статье описаны его свойства, а также влияние на когнитивные функции и возможности применения у детей и подростков с эпилепсией и синдромом дефицита внимания и гиперактивности.
Ключевые слова: ламотриджин, Сейзар, эпилепсия, синдром дефицита внимания и гиперактивности.
________________________________________________
Lamotrigine (Seizar) is a broad-spectrum antiepileptic drug, has relatively mild side effects, more than a quarter of a century with success is used in pediatric epileptology. The article describes its properties, as well as the impact on cognitive functions and use in children and adolescents with epilepsy and attention deficit hyperactivity disorder.
Key words: lamotrigine, Seizar, epilepsy, attention deficit disorder and of hyperactivity.
1. Besag FM, Dulac O, Alving J, Mullens EL. Long-term safety and efficacy of lamotrigine (Lamictal) in paediatric patients with epilepsy. Seizure 1997; 6 (1): 51–6.
2. Besag FM et al. Successful re-introduction of lamotrigine after initial rash. Seizure 2000; 9 (4): 282–6.
3. Bennett-Back O, Keren A, Zelnik N. Attention-deficit hyperactivity disorder in children with benign epilepsy and their siblings. Pediatr Neurol 2011; 44: 187–92.
4. Arzimanoglou A. Treatment options in pediatric epilepsy syndromes. Epileptic disorders 2002; 3: 217–25.
5. Barron TF, Hunt SL, Hoban TF, Price ML. Lamotrigine monotherapy in children. Pediatr Neurol 2000; 23 (2): 160–3.
6. Ben-Menachem E, Scheepers B, Stodieck S. Epilepsy: fron consesus to daily practise. Acta Neurol Scand 2003; 108 (Suppl. 180): 5–15.
7. Dulac О. The use of Lamotrigine in children. Rev Contemp Pharmacother 1994; 5: 133–9.
8. Schlumberger E, Chavez F, Dulac O, Moszkowski J. Open study with lamotrigine (LTG) in child epilepsy. Seizure 1992; 1 (Suppl. 3): 9–21.
9. Frank LM, Casale E, Womble G, Manasco P. Lamictal is effective for the treatment of newly – diagnosed typical absence seizures in children and adolescents. Ann Neurol 1997; 42 (3): 489.
10. Duchowny M, Pellock JM, Graf WD et al. A placebo-controlled trial of lamotrigine add-on therapy for partial seizures in children. Lamictal Pediatric Partial Seizure Study Group. Neurology 1999; 53: 1724–31.
11. Edwards KR, Sdckellares JC, Vuong A et al. Lamotrigine Monotherapy Improves Depressive Symptoms in Epilepsy: A Double Blind Comparison with Valproate. Epilepsy Behav 2001; 2: 28–36.
12. Petrukhin AS, Mukhin KYu, Medvedev MI. Lamictal in the treatment of epilepsy in children. Epilepsia 1996; 37 (Suppl. 3): 14.
13. Solowiej E, Sobaniec W, Kozik A, Ujma-Czapska B. The use of lamotrigine monotherapy in children with newly diagnosed partial epilepsy. Neurol Neurochir Pol 2000; 33 (Suppl. 1): 129–41.
14. Coppola G, Licciardi F, Sciscio N et al. Lamotrigine as first-line drug in childhood absence epilepsy: a clinical and neurophysiological study. Brain Dev 2004; 26 (1): 26–9.
15. Petrukhin AS, Mukhin KYu, Medvedev MI. Lamotrigine in the treatment of cryptogenic generalized epilepsy. Epilepsia 1997; 38 (Suppl. 3.): 66.
16. Betts Т, Goodwin G, Withers RM, Yuen AWC. Human safety of Lamotrigine. Epilepsia 1991; 32 (Suppl. 2): 17–21.
17. Genton P, Baue J, Duncan S et al. On the association Between Valproat and Polycystic Ovary Syndrome. Epilepsia 2001; 42 (3): 295–304.
18. Isojarvi JI, Tapanainen JS. Valproate, hyperandrogenism, and polycystic ovaries: a report of 3 cases. Neurology 2000; 57 (7): 1064–8.
19. Sabers A, Dam M, Rogvi A et al. Epilepsy and pregnancy: lamotrigine as main drug used. Acta Neurol Scand 2004; 109 (1): 9–13.
20. Devinsky O, Vuong A, Hammer A, Barrett PS. Stable weight during lamotrigine therapy: a review of 32 studies. Neurology 2000; 54: 973–5.
21. Петрухин А.С., Бурд Г.С., Мухин К.Ю. и др. Ламиктал в лечении эпилепсии у детей. Соц. и клин. психиатрия. 1996; 6 (3): 121–4. / Petrukhin A.S., Burd G.S., Mukhin K.Iu. i dr. Lamiktal v lechenii epilepsii u detei. Sots. i klin. psikhiatriia. 1996; 6 (3): 121–4. [in Russian]
22. Gucuyener K et al. Use of methylphenidate for attention-deficit hyperactivity disorder in patients with epilepsy or electroencephalographic abnormalities. J Child Neurol 2003; 18: 109–12.
________________________________________________
1. Besag FM, Dulac O, Alving J, Mullens EL. Long-term safety and efficacy of lamotrigine (Lamictal) in paediatric patients with epilepsy. Seizure 1997; 6 (1): 51–6.
2. Besag FM et al. Successful re-introduction of lamotrigine after initial rash. Seizure 2000; 9 (4): 282–6.
3. Bennett-Back O, Keren A, Zelnik N. Attention-deficit hyperactivity disorder in children with benign epilepsy and their siblings. Pediatr Neurol 2011; 44: 187–92.
4. Arzimanoglou A. Treatment options in pediatric epilepsy syndromes. Epileptic disorders 2002; 3: 217–25.
5. Barron TF, Hunt SL, Hoban TF, Price ML. Lamotrigine monotherapy in children. Pediatr Neurol 2000; 23 (2): 160–3.
6. Ben-Menachem E, Scheepers B, Stodieck S. Epilepsy: fron consesus to daily practise. Acta Neurol Scand 2003; 108 (Suppl. 180): 5–15.
7. Dulac О. The use of Lamotrigine in children. Rev Contemp Pharmacother 1994; 5: 133–9.
8. Schlumberger E, Chavez F, Dulac O, Moszkowski J. Open study with lamotrigine (LTG) in child epilepsy. Seizure 1992; 1 (Suppl. 3): 9–21.
9. Frank LM, Casale E, Womble G, Manasco P. Lamictal is effective for the treatment of newly – diagnosed typical absence seizures in children and adolescents. Ann Neurol 1997; 42 (3): 489.
10. Duchowny M, Pellock JM, Graf WD et al. A placebo-controlled trial of lamotrigine add-on therapy for partial seizures in children. Lamictal Pediatric Partial Seizure Study Group. Neurology 1999; 53: 1724–31.
11. Edwards KR, Sdckellares JC, Vuong A et al. Lamotrigine Monotherapy Improves Depressive Symptoms in Epilepsy: A Double Blind Comparison with Valproate. Epilepsy Behav 2001; 2: 28–36.
12. Petrukhin AS, Mukhin KYu, Medvedev MI. Lamictal in the treatment of epilepsy in children. Epilepsia 1996; 37 (Suppl. 3): 14.
13. Solowiej E, Sobaniec W, Kozik A, Ujma-Czapska B. The use of lamotrigine monotherapy in children with newly diagnosed partial epilepsy. Neurol Neurochir Pol 2000; 33 (Suppl. 1): 129–41.
14. Coppola G, Licciardi F, Sciscio N et al. Lamotrigine as first-line drug in childhood absence epilepsy: a clinical and neurophysiological study. Brain Dev 2004; 26 (1): 26–9.
15. Petrukhin AS, Mukhin KYu, Medvedev MI. Lamotrigine in the treatment of cryptogenic generalized epilepsy. Epilepsia 1997; 38 (Suppl. 3.): 66.
16. Betts Т, Goodwin G, Withers RM, Yuen AWC. Human safety of Lamotrigine. Epilepsia 1991; 32 (Suppl. 2): 17–21.
17. Genton P, Baue J, Duncan S et al. On the association Between Valproat and Polycystic Ovary Syndrome. Epilepsia 2001; 42 (3): 295–304.
18. Isojarvi JI, Tapanainen JS. Valproate, hyperandrogenism, and polycystic ovaries: a report of 3 cases. Neurology 2000; 57 (7): 1064–8.
19. Sabers A, Dam M, Rogvi A et al. Epilepsy and pregnancy: lamotrigine as main drug used. Acta Neurol Scand 2004; 109 (1): 9–13.
20. Devinsky O, Vuong A, Hammer A, Barrett PS. Stable weight during lamotrigine therapy: a review of 32 studies. Neurology 2000; 54: 973–5.
21. Petrukhin A.S., Burd G.S., Mukhin K.Iu. i dr. Lamiktal v lechenii epilepsii u detei. Sots. i klin. psikhiatriia. 1996; 6 (3): 121–4. [in Russian]
22. Gucuyener K et al. Use of methylphenidate for attention-deficit hyperactivity disorder in patients with epilepsy or electroencephalographic abnormalities. J Child Neurol 2003; 18: 109–12.
Авторы
О.Л.Бадалян, А.А.Савенков
ФГБОУ ВО «Российский национальный исследовательский медицинский университет им. Н.И.Пирогова» Минздрава России. 117997, Россия, Москва, ул. Островитянова, д. 1
N.I.Pirogov Russian National Research Medical University of the Ministry of Health of the Russian Federation. 117997, Russian Federation, Moscow, ul. Ostrovitianova, d. 1